Welcome to our dedicated page for Clorox Co Del SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clorox Company (NYSE: CLX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a consumer products manufacturer in the polish and other sanitation good manufacturing industry. This SEC filings page aggregates those disclosures and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
Key filings for CLX include annual reports on Form 10-K, which typically describe the company’s business segments—Health and Wellness, Household, Lifestyle and International—along with risk factors, discussion of strategy and detailed financial statements. Quarterly reports on Form 10-Q update investors on interim performance, including segment results, margin drivers, cash flow and the impact of initiatives such as the U.S. enterprise resource planning (ERP) transition and portfolio changes like the divestiture of the Better Health Vitamins, Minerals and Supplements business.
Clorox also uses current reports on Form 8-K to disclose material events. Recent 8-K filings have covered quarterly and annual financial results, supplemental financial information, and matters submitted to a shareholder vote at the annual meeting, including director elections, advisory votes on executive compensation and ratification of the independent registered public accounting firm. Other 8-Ks may address leadership changes or other significant corporate developments.
The company’s proxy statement on Form DEF 14A provides additional detail on governance, board composition, executive compensation, strategic priorities such as the IGNITE strategy and oversight of areas like risk management and sustainability. For those interested in ownership and compensation, this document is a primary source.
On this page, filings are updated as they are released to EDGAR. AI-generated highlights and plain-language explanations help clarify complex topics such as non-GAAP measures (for example, organic sales growth, adjusted EBIT and adjusted EPS), the effects of the ERP transition on reported results, and the rationale behind portfolio actions. Users can also review any available insider-related disclosures, such as Form 4 filings, to see reported transactions by directors and officers.
Whether you are analyzing Clorox’s segment performance, reviewing governance practices, or tracking shareholder votes and executive compensation, this filings hub offers structured access to the company’s regulatory record with tools designed to make lengthy documents more approachable.
Clorox (CLX) director and EVP Stacey Grier reported transactions dated 10/03/2025 showing settlement of a 2022 performance unit award and related share movements. The reporting person received 9,913 shares upon settlement of the performance unit grant, which she elected to defer under the 2005 Stock Incentive Plan. The company withheld 233 shares to cover taxes on performance stock units and 799 shares for taxes on restricted stock. After these transactions and including 1,004 dividend-reinvested shares, the filing shows beneficial ownership fell from 33,235 shares to 32,203.
Executive stock vesting and tax-related share withholdings: The Chief Operating Officer reported transactions on 10/03/2025 involving 15,489 shares issued upon settlement of a 2022 performance unit grant at an indicated price of $122.25 per share. The filing shows the company withheld 2,755 shares to satisfy tax obligations for restricted stock and 7,436 shares to satisfy tax obligations for performance stock units. After these transactions the reporting person beneficially owned 69,313 shares (including 739 dividend-reinvested shares).
Insider transaction summary: An executive officer of Clorox Co. (CLX) reported transactions on 10/03/2025 that settled a 2022 performance-unit grant into 9,293 shares of common stock at a per-share price of $122.25. The filing shows two share withholdings to satisfy tax obligations: 1,653 shares and 3,488 shares, each recorded at $122.25. Following these transactions the reporting person beneficially owns 38,280 shares (this total includes 534 shares from dividend reinvestment). The Form 4 was signed by an attorney-in-fact on 10/07/2025.
Insider transactions at Clorox Co (CLX): an executive reported multiple equity transactions on 10/03/2025. The reporting person acquired 8,672 shares through settlement of a 2022 performance unit grant at an effective price of $122.25, increasing direct holdings to 35,667 shares. The filing also shows withholding of 1,904 and 3,629 shares to satisfy tax obligations tied to restricted stock and performance stock units, respectively, and 462 shares from dividend reinvestment. Additionally, 612.574 shares are held indirectly via the company 401(k). The form was signed by an attorney-in-fact on 10/07/2025.
Clorox insider transaction: The company's EVP & Chief Financial Officer received 2,581 shares upon settlement of a 2022 Performance Unit Grant that vested on 10/03/2025 at a reported per-share value of $122.25. The filing shows two share-withholdings to satisfy tax obligations: 421 shares withheld for restricted stock taxes and 893 shares withheld for performance stock unit taxes. After these transactions, the reporting person beneficially owned 20,864 shares (which includes 167 dividend-reinvestment shares).
Nina Barton, EVP-Group Pres–Care & Conn at Clorox Co. (CLX), reported a sale of 622 shares of Clorox common stock on 10/03/2025 at a price of $122.25 per share. The transaction is recorded as code F and is explained as withholding of shares to satisfy tax obligations related to the vesting of restricted stock. After the transaction, Ms. Barton beneficially owns 27,895 shares, which includes 21 shares acquired via a dividend reinvestment feature of the Company’s Stock Incentive Plan.
The report was signed by an attorney-in-fact on 10/07/2025. The filing indicates a routine tax-withholding disposition rather than an open-market sale, and it shows continued significant insider ownership by an executive responsible for the company’s care and consumer connections businesses.
Clorox (CLX) reported a mixed fiscal year 2025 driven by strong margin recovery and cost actions but limited top-line growth. Net sales were essentially flat at $7,104 versus $7,093 a year earlier as ERP-transition shipments, divestitures and a softer second half offset a strong first half. Gross margin expanded by 220 basis points to 45.2, largely from cost savings, higher volume and benefits from divestitures. Reported earnings before income taxes rose to $1,078 and diluted EPS increased to $6.52, up 190 from the prior year. Economic Profit increased to $756. Operating cash flow improved to $981 and free cash flow was $761 (~10.7 of net sales). The company completed the divestiture of the Better Health VMS business, announced a 2 dividend increase in July 2025, and noted ongoing impacts from the August 2023 cyberattack and the ERP transition.
Christopher J. Williams, a director of Clorox Co. (CLX), reported two grants of Deferred Stock Units (DSUs) on a Form 4. On 08/29/2025 he received 199.8083 DSUs through dividend reinvestment; on 09/30/2025 he received 212.8954 DSUs in lieu of quarterly director fees. The DSUs are 1-for-1 and will be settled in Clorox common stock upon the reporting person’s retirement or other termination of director service. Following these transactions, the reporting person beneficially owns 19,458.9483 shares (reported as 19,246.0529 before the 09/30/2025 grant).
Russell J. Weiner, a director of Clorox Co. (CLX), received additional deferred stock units (DSUs) under the company's Independent Directors' Deferred Compensation Plan. On 08/29/2025 he was credited with 156.7731 DSUs via dividend reinvestment and on 09/30/2025 he received 253.4469 DSUs in lieu of quarterly director fees. The reported DSUs will be settled 100% in Clorox common stock when the reporting person retires or otherwise terminates service as a director. After these transactions the reporting person beneficially owned 15,354.2406 DSUs (expressed as common stock equivalents) held directly.
Matthew J. Shattock, a director of Clorox Co. (CLX), reported two grants of Deferred Stock Units (DSUs) that increase his notional holdings. On 08/29/2025 he received 172.9087 DSUs through dividend reinvestment, and on 09/30/2025 he received 415.6529 DSUs in lieu of quarterly director fees.
The report shows DSUs convert on a 1-for-1 basis into common stock at the director's retirement or termination and that the total DSUs after the September grant equal 17,070.6618 shares. Both grants are reported as direct beneficial ownership and have a $0.00 per-unit price because they are deferred compensation awards.